Improved SpO 2 Accuracy Now Available for All Patient Populations IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that RD SET ® sensors with Masimo Measure-through Motion and ...

Masimo Corporation MASI received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering improved ...

Pulse oximetry screening (POS) is an effective tool to detect critical congenital heart disease (CCHD) in asymptomatic term infants, but its value in the neonatal intensive care unit (NICU) requires ...

NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in ...

This study is designed to answer one of the fundamental gaps in knowledge in the resuscitation of preterm infants at birth: What is the optimal target oxygen saturation (SpO2) range that increases ...

Pulse oximetry is a simple, noninvasive, painless test that can detect mild hypoxemia, a feature of many forms of CCHD that is easy to miss on physical examination. 5 As an adjunct to the standard ...

Pulse oximetry is a widely used monitoring method for measuring blood oxygen levels and pulse rate. In newborn babies, pulse oximetry can help clinicians conduct screening tests for lung or heart ...

Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...

Although current pulse-oximetry technology cannot detect every cardiac defect, the rate of missed CCHD diagnoses is much higher when screening is based on physical examination alone. Health-care ...